Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
BP4 S.r.l., a ten percent owner of MILESTONE SCIENTIFIC INC. (NASDAQ:MLSS), has reported selling shares of common stock in three separate transactions. The sales come as the stock trades near $0.67, down about 43% over the past six months. According to a Form 4 filing with the Securities and Exchange Commission, the sales totaled $62,798, with prices ranging from $0.6698 to $0.6905.
On July 3, 2025, BP4 S.r.l. sold 50,853 shares of MILESTONE SCIENTIFIC INC. at a price of $0.6698 per share. Following this, on July 7, 2025, the entity sold 30,558 shares at $0.6808 per share. The final transaction occurred on July 8, 2025, with 11,489 shares sold at $0.6905 per share.
Following these transactions, BP4 S.r.l. directly owns 9,308,799 shares of MILESTONE SCIENTIFIC INC. The sales were signed off by Dr. Pedro Palau, Liquidator, on July 10, 2025.
In other recent news, Milestone Scientific (NYSE:MLSS) Inc. has continued to receive support from Benchmark analysts, who reiterated a Speculative Buy rating and maintained a $1.25 price target for the company’s shares. The company ended the first quarter with a solid financial position, holding $2.2 million in cash and no debt. Milestone Scientific is actively working to expand its presence in the Medicare market for pain management through its CompuFlo System, which has already secured coverage from three out of twelve Medicare Administrative Contractors. The company aims to obtain additional coverage from the remaining MACs and pursue reimbursement from private payors, potentially expanding its market to nine million procedures.
Additionally, Milestone Scientific has appointed Shanth Thiyagalingam to its Board of Directors to drive growth. Thiyagalingam brings over two decades of experience in the medical device and pharmaceutical sectors, which is expected to support the company’s expansion strategies. His previous leadership roles include CEO of PainTEQ, where he successfully managed commercial strategies and operations. This strategic board appointment aligns with Milestone Scientific’s focus on leveraging favorable Medicare Part B payment rates and a Federal Supply Schedule contract to enhance market adoption. The company’s innovative injection technologies, including its proprietary DPS Dynamic Pressure Sensing Technology®, are central to its product development strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.